TBR-065

Tiburio is developing TBR-065, a dopamine-somatostatin chimeric compound, for the treatment of rare endocrine diseases.

Tiburio is developing TBR-065, a dopamine-somatostatin chimeric compound, for the treatment of rare endocrine diseases.

Tiburio is also developing a second compound, TBR-065, for the treatment of rare endocrine disorders. TBR-065 is a dopamine-somatostatin agonist from the same family as TBR-760 and has been demonstrated to be safe and well-tolerated in clinical studies.

Tiburio is accumulating additional data to determine the optimal indication for TBR-065.

PreclinicalPhase 1Phase 2Phase 3
Preclinical
Phase 1
Phase 2
Phase 3